Table 5 Disease-specific survival in patients with resectable high-grade salivary gland cancers (n = 103)
Univariate model | Multivariate model | |||||
|---|---|---|---|---|---|---|
HR | 95% CI | P | HR | 95% CI | P | |
Age (years) | 1.012 | 0.980–1.045 | 0.464 | |||
Gender (Male/Female) (83/20) | 2.325 | 0.697–7.756 | 0.170 | |||
Primary site | ||||||
Parotid gland (69) | 1 (Ref.) | |||||
Non-parotid gland (34) | 1.409 | 0.644–3.081 | 0.390 | |||
TN categories | ||||||
T3–4/T1–2 (45/58) | 2.011 | 0.919–4.403 | 0.080 | 0.744 | 0.285–1.938 | 0.544 |
N1–3/N0 (48/55) | 6.115 | 2.509–14.903 | < 0.001 | 10.211 | 3.485–29.919 | < 0.001 |
Pathological diagnosis | ||||||
Salivary duct carcinoma (67) | 1 (Ref.) | |||||
Squamous cell carcinoma, primary (9) | 0.627 | 0.145–2.718 | 0.533 | |||
Adenoid cystic carcinoma, solid type (8) | 1.557 | 0.457–5.308 | 0.479 | |||
Mucoepidermoid carcinoma, high-grade (7) | 0.541 | 0.072–4.069 | 0.550 | |||
Adenocarcinoma, high-grade (6) | 0.439 | 0.058–3.302 | 0.424 | |||
Others (6) | 1.978 | 0.455–8.604 | 0.363 | |||
Treatment modalities | ||||||
Surgery (13) | 1 (Ref) | 1 (Ref) | ||||
Surgery + radiation (62) | 1.266 | 0.377–4.248 | 0.702 | 0.742 | 0.207–2.655 | 0.646 |
Surgery + radiation + chemotherapy (28) | 0.433 | 0.087–2.155 | 0.307 | 0.121 | 0.022–0.677 | 0.016 |
Surgery for primary tumor (R1/R0) (6/97) | 0.045 | 0.000–39.169 | 0.369 | |||
Neck dissection/no neck dissection (72/31) | 1.871 | 0.780–4.488 | 0.161 | |||
Pathological risk factors | ||||||
Perineural invasion (Y/N) (13/90) | 0.042 | 0.000–12.297 | 0.274 | |||
Lymphovascular invasion (Y/N) (16/87) | 0.043 | 0.000–20.431 | 0.317 | |||
Extra-parenchymal extension (Y/N) (45/58) | 2.156 | 0.979–4.750 | 0.057 | |||
Extra-capsular spread (Y/N) (26/77) | 2.547 | 1.065–6.092 | 0.036 | 1.363 | 0.509–3.649 | 0.538 |